Why Physical Activity Should Be Considered in Clinical Trials for COVID-19 Vaccines: A Focus on Risk Groups

dc.creatorBortolini, Miguel Junior Sordi
dc.creatorPetriz, Bernardo
dc.creatorMineo, José Roberto
dc.creatorResende, Rafael de Oliveira
dc.date2023-02-11T13:08:09Z
dc.date2023-02-11T13:08:09Z
dc.date2022
dc.date.accessioned2023-09-26T21:00:25Z
dc.date.available2023-09-26T21:00:25Z
dc.identifierBORTOLINI, Miguel Junior Sordi et al. Why Physical Activity Should Be Considered in Clinical Trials for COVID-19 Vaccines: A Focus on Risk Groups. International Journal of Environmental Research and Public Health, v. 19, 1853, p. 1 - 10, 2022.
dc.identifier1660-4601
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/57020
dc.identifier10.3390/ijerph19031853
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8867612
dc.descriptionSince the World Health Organization declared the global COVID-19 state of emergency in early 2020, several vaccine candidates have emerged to control SARS-CoV-2, and some of them have been approved and implemented in vaccination campaigns worldwide. Although clinical trials for these vaccines have been carried out using highly controlled methods with accurate immunological tests, clinical questionnaires did not include questions concerning the physical activity profile among volunteers. It has been well established that physical activity plays a pivotal role in the immune response after vaccination, led by the activation of cytokines, antibodies, and cells. This concept should have been considered when evaluating the efficacy of COVID-19 vaccine candidates, particularly in elderly and obese people. Here, we discuss data from the literature providing strong evidence regarding the importance of analyzing physical activity parameters to improve the accuracy of clinical trials on assessing the efficacy of vaccine candidates.
dc.formatapplication/pdf
dc.languageeng
dc.publisherMDPI
dc.rightsopen access
dc.subjectCOVID-19
dc.subjectAtividade física
dc.subjectSARS-CoV-2
dc.subjectVacina
dc.subjectTestes clínicos
dc.subjectPhysical activity
dc.subjectCOVID-19
dc.subjectSARS-CoV-2
dc.subjectVaccine
dc.subjectClinical trials
dc.titleWhy Physical Activity Should Be Considered in Clinical Trials for COVID-19 Vaccines: A Focus on Risk Groups
dc.typeArticle


Este ítem pertenece a la siguiente institución